Nomir Medical Receives Frost & Sullivan Award for Development of Noveon

[Guest guest]

PRESS RELEASE

Nomir Medical Receives Frost & Sullivan Award for Development of Noveon®

http://www.marketwatch.com/news/story/nomir-medical-receives-frost-/story.aspx?g\

uid=%7B5C74C123-68AC-4BF1-9E10-86258451FAED%7D & dist=msr_2

Last update: 9:03 a.m. EST March 4, 2009

WALTHAM, Mass., Mar 04, 2009 (BUSINESS WIRE) -- Nomir Medical Technologies, a

leader in the development of optical energy technologies for medical

applications, has been awarded the 2009 Frost & Sullivan North American

Technology Innovation of the Year Award for Advanced Microbial Destruction

Technologies for its development of the Noveon® technology platform. The

Noveon is a light-based system that utilizes two discrete, near-infrared

wavelengths at low power to eliminate bacterial and fungal infections through a

photo-biological method-of-action. The system's unique, near-infrared

photo-inactivation effect preserves healthy tissue and promotes recovery.

The Award will be presented at Frost & Sullivan's 2009 Excellence in Medical

Technologies & Life Sciences Awards Banquet in San Francisco on March 18, 2009.

" Nomir Medical is honored to receive this significant Award from Frost &

Sullivan, " said Burtt, President and CEO of Nomir Medical. " This

recognition illustrates the potentially breakthrough nature of the Noveon as a

new treatment paradigm for bacterial and fungal infections and as an alternative

to pharmacological therapy. This technology platform has thus far been validated

in human clinical trials in both onychomycosis and MRSA and we believe that its

potential utility extends far beyond these indications. We look forward to soon

reporting results from the pivotal trial in onychomycosis and, pending FDA

approval of the device for this indication, commercializing Noveon for

onychomycosis treatment. "

The Frost & Sullivan Award is presented to a company (or individual) that has

carried out new research that has resulted in innovation(s) that have or are

expected to bring significant contributions to the medical field, and recognizes

the quality, depth and vision of a company's research and development program.

In considering Award recipients, the Frost & Sullivan analyst team considers the

pace of research and technology innovation; the significance or potential

relevance of the innovation to the overall industry; and criteria such as the

significance of the innovation in the industry, potential of the products of

innovation to become industry-standard and the competitive advantages of the

innovation vis-a-vis other related innovations.

After multiple IRB human pilot studies with Noveon against onychomycosis (toe

nail fungus), Nomir initiated an FDA pivotal study of its Noveon device for this

indication in May 2008, an integral step for FDA clearance of the application.

Nomir has also completed two IRB human studies with Noveon against

methicillin-resistant Staphylococcus aureus (MRSA) carriage and infection in the

nares (nose). Based on positive data from these studies, Nomir is initiating a

pilot study with Noveon for the reduction of bioburden in diabetic foot ulcers.

Nomir Medical also recently announced a second FDA 510(k) clearance of the

Company's advanced Noveon system. With this clearance, the device may now be

utilized during procedures of the skin, subcutaneous tissues and nasal passages,

for applications in podiatry, dermatology, plastic surgery, and otolaryngology.

About Nomir

Nomir Medical Technologies, Inc. is a medical device and photobiology company

with a product pipeline of optical energy therapeutics being developed for

multiple clinical applications. Nomir's light-based systems target the

elimination of bacterial and fungal infections, while also promoting healthy

tissue recovery. This potential therapy-altering technology may enhance the

effectiveness of, or even reduce the need for antibiotics and antifungal agents,

and may be associated with fewer treatment side-effects. Nomir has a broad

patent portfolio with multiple patents and patents pending on systems, methods

and unique photobiological mechanism claims for near-infrared photodamage to

bacterial and fungal pathogens.

www.nomirmedical.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate

growth and achieve best in class positions in growth, innovation and leadership.

The company's Growth Partnership Service provides the CEO and the CEO's Growth

Team with disciplined research and best practice models to drive the generation,

evaluation and implementation of powerful growth strategies. Frost & Sullivan

leverages over 45 years of experience in partnering with Global 1000 companies,

emerging businesses and the investment community from 31 offices on six

continents. To join our Growth Partnership, please visit http://www.frost.com.

Forward-looking statements

Certain statements contained in this press release containing words like

believe, intend, may, expect, project and other similar expressions are

forward-looking statements involving a number of risks and uncertainties.

Factors that can cause actual results to differ materially from those projected

in the Company's forward-looking statements include the following: market

acceptance of our technologies, therapies, and products; our ability to obtain

financing; our financial and technical resources relative to those of our

competitors; our ability to keep up with rapidly changing technologies;

government regulations of our technologies; our ability to assert and enforce

our intellectual property rights and protect our proprietary technologies; the

ability to attract and retain key employees; the ability to obtain and develop

partnership opportunities; the timing of commercial product launches; the

ability to achieve key milestones in key products and other risks factors from

time to time in the Company's announcements.

SOURCE: Nomir Medical Technologies

Media:

MacDougall Biomedical Communications

Greenleaf-Conrad, 781-235-3060

or

Nomir Medical Technologies, Inc.

Burtt, 781-893-1000 ext. 403

Chief Executive Officer